semaglutide cardiac FDA Clears For Risk Reduction in Diabetic Patients Semaglutide cardiovascular outcomes align more

doi: 10.2337/dc24-1678

K., O'Grady K., Caulfield J

It is recommended to monitor the GPT to monitor hepatic injury

Many plan sponsors are receiving frequent questions from employees asking why weight-loss drugs like semaglutide (Wegovy) are not covered under their benefits plan despite being widely perceived as an effective treatment

It may also be part of therapy to treat Leber optic atrophy (an inherited optic neuropathy associated with a deficiency in vitamin B12).

Visceral fat, the kind stored around organs in the abdominal cavity rather than under the skin, is directly linked to metabolic syndrome, insulin resistance, and cardiovascular risk